Sheetal Shah

445 total citations
17 papers, 148 citations indexed

About

Sheetal Shah is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Sheetal Shah has authored 17 papers receiving a total of 148 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 9 papers in Molecular Biology and 6 papers in Genetics. Recurrent topics in Sheetal Shah's work include Multiple Myeloma Research and Treatments (7 papers), Protein Degradation and Inhibitors (6 papers) and Acute Myeloid Leukemia Research (5 papers). Sheetal Shah is often cited by papers focused on Multiple Myeloma Research and Treatments (7 papers), Protein Degradation and Inhibitors (6 papers) and Acute Myeloid Leukemia Research (5 papers). Sheetal Shah collaborates with scholars based in United States, Spain and Italy. Sheetal Shah's co-authors include Patricia E. Kuwabara, Jacalyn Rosenblatt, Kenneth C. Anderson, Noopur Raje, Paul G. Richardson, Craig C. Hofmeister, Jacob P. Laubach, Ajay K. Nooka, Mohamed H. Zaki and Yvonne A. Efebera and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Oncology and Blood.

In The Last Decade

Sheetal Shah

14 papers receiving 144 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sheetal Shah United States 7 91 69 41 34 26 17 148
Jideofor Ezike United States 3 196 2.2× 22 0.3× 27 0.7× 5 0.1× 21 0.8× 4 237
Varun Katta United States 3 206 2.3× 6 0.1× 19 0.5× 29 0.9× 12 0.5× 4 225
Nour J. Abdulhay United States 6 122 1.3× 27 0.4× 2 0.0× 5 0.1× 26 1.0× 7 160
Bhavini Rana United States 4 191 2.1× 3 0.0× 15 0.4× 14 0.4× 7 0.3× 8 330
George E. Ghanim United Kingdom 7 190 2.1× 4 0.1× 28 0.7× 7 0.2× 3 0.1× 9 252
Eshwar Meduri United Kingdom 6 187 2.1× 24 0.3× 1 0.0× 9 0.3× 9 0.3× 11 234
Marina Borschiwer Germany 4 157 1.7× 3 0.0× 13 0.3× 9 0.3× 3 0.1× 4 186
Benjamin Holmes United States 4 176 1.9× 3 0.0× 10 0.2× 8 0.2× 4 0.2× 5 186
Manuel Allhoff Germany 6 210 2.3× 10 0.1× 2 0.0× 9 0.3× 10 0.4× 6 250
Tyler Hansen United States 8 217 2.4× 3 0.0× 102 2.5× 17 0.5× 2 0.1× 13 280

Countries citing papers authored by Sheetal Shah

Since Specialization
Citations

This map shows the geographic impact of Sheetal Shah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sheetal Shah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sheetal Shah more than expected).

Fields of papers citing papers by Sheetal Shah

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sheetal Shah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sheetal Shah. The network helps show where Sheetal Shah may publish in the future.

Co-authorship network of co-authors of Sheetal Shah

This figure shows the co-authorship network connecting the top 25 collaborators of Sheetal Shah. A scholar is included among the top collaborators of Sheetal Shah based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sheetal Shah. Sheetal Shah is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
3.
Shah, Sheetal, et al.. (2024). CONSUMER VALUATION OF GREEN PRODUCTS: INTERPLAY BETWEEN MARKETING CLAIMS, CERTIFICATION, AND BUYING INTENTIONS. ShodhKosh Journal of Visual and Performing Arts. 5(7).
4.
5.
6.
7.
Shah, Sheetal & Anuradha Sharma. (2018). Parents' forgiveness and coping styles as predictors of Children's self-esteem. Journal of Indian Association for Child and Adolescent Mental Health. 14(4). 109–124. 1 indexed citations
8.
Siegel, David S., Niels W.C.J. van de Donk, Pieter Sonneveld, et al.. (2016). A phase 1b study of durvalumab (MEDI4736) alone or in combination with pomalidomide (POM) with or without low dose-dexamethasone (LoDEX) in patients (pts) with relapsed and refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 34(15_suppl). TPS8072–TPS8072. 3 indexed citations
9.
Richardson, Paul G., Craig C. Hofmeister, Noopur Raje, et al.. (2015). A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005). Blood. 126(23). 3036–3036. 11 indexed citations
10.
Richardson, Paul G., Craig C. Hofmeister, Noopur Raje, et al.. (2014). MM-005: Phase 1 trial of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) in lenalidomide (LEN)-refractory and proteasome inhibitor (PI)-exposed myeloma.. Journal of Clinical Oncology. 32(15_suppl). 8589–8589. 5 indexed citations
11.
Kutlar, Abdullah, et al.. (2013). Pomalidomide In Sickle Cell Disease: Phase I Study Of a Novel Anti-Switching Agent. Blood. 122(21). 777–777. 9 indexed citations
12.
Richardson, Paul G., Craig C. Hofmeister, David S. Siegel, et al.. (2013). MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM). Blood. 122(21). 1969–1969. 17 indexed citations
13.
Richardson, Paul G., Craig C. Hofmeister, David S. Siegel, et al.. (2013). MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 31(15_suppl). 8584–8584. 7 indexed citations
14.
15.
Shah, Sheetal, et al.. (2011). Insecticide detoxification indicator strains as tools for enhancing chemical discovery screens. Pest Management Science. 68(1). 38–48. 14 indexed citations
16.
Wendtner, Clemens‐Martin, Daruka Mahadevan, Stephan Stilgenbauer, et al.. (2008). Preliminary Results of a Phase 1/2, Multi-Center, Open-Label Study (CLL- 001) Investigating a Stepwise Dose-Escalation Schedule of Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia.. Blood. 112(11). 2104–2104. 7 indexed citations
17.
Kuwabara, Patricia E. & Sheetal Shah. (1994). Cloning by synteny: identifying C.briggse homologues of C.elegans genes. Nucleic Acids Research. 22(21). 4414–4418. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jideofor Ezike Breakdown of academic impact, for papers by Varun Katta Breakdown of academic impact, for papers by Nour J. Abdulhay Breakdown of academic impact, for papers by Bhavini Rana Breakdown of academic impact, for papers by George E. Ghanim Breakdown of academic impact, for papers by Eshwar Meduri Breakdown of academic impact, for papers by Marina Borschiwer Breakdown of academic impact, for papers by Benjamin Holmes Breakdown of academic impact, for papers by Manuel Allhoff Breakdown of academic impact, for papers by Tyler Hansen
Rankless by CCL
2026